Company news

Enlivex Ltd. news in 2020

Enlivex Ltd.'s news releases, calls and decks from 2020, newest first.

View company

Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy

December 6, 2020

Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients

December 2, 2020

Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra

November 17, 2020

Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors

November 16, 2020

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, and Ulcerative Colitis with Allocetra Immunotherapy

November 4, 2020

Enlivex: Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients

November 2, 2020

Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients

October 21, 2020

Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition

September 30, 2020

Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy

September 15, 2020

Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy

August 24, 2020

Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure

August 9, 2020

Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy

June 17, 2020

Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients

May 6, 2020

Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis

March 17, 2020

Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering

March 4, 2020

Enlivex Therapeutics Announces $16.75 Million Registered Direct Offering

March 1, 2020

Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering

February 25, 2020

Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure

February 23, 2020

Enlivex Therapeutics Announces $8.0 Million Registered Direct Offering

February 23, 2020

Decks in 2020